The acute and short-time effect of supplementation with the combination of n−3 fatty acids and acetylsalicylic acid on platelet function and plasma lipids

Svaneborg, Niels; Kristensen, Steen Dalby; Hansen, Lene M.; Büllow, Inge; Husted, Steen; Schmidt, Erik Berg

doi:10.1016/s0049-3848(02)00010-5

Cited by 28 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results represent evidence on: clinical outcomes of effectiveness from 19 RCTs [37-55] (Table 1); intermediate surrogate outcomes from 52 RCTs and two non-RCTs [38,39,41,43,45,48-94] (Tables 2 and 3); harms identified from 52 RCTs and a single retrospective cohort study [37-41,43,45-48,50-68,70-73,76-78,80-84,87,90-99] (data available online[100]); and lastly direct evidence of pharmacokinetic data on interactions between supplements and CV drugs from 11 RCTs [37,60,63,66,71,83,96,98](data available online [100]).…”

Section: Resultsmentioning

confidence: 99%

“…Insufficient evidence was available from 22 studies (21 RCTs and one retrospective cohort study) which examined omega-3 fatty acids plus statins [37,38,41,52,72,76,81-83,96,103], aspirin [46,51,77,80,84], aspirin and clopidogrel [99], aspirin in combination with dipyridamole and calcium channel blockers [51], warfarin [46,54], ramipril and/or irbesartan [78], or fenofibrate [55]. These studies were generally small and underpowered.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Interactions of commonly used dietary supplements with cardiovascular drugs: a systematic review

et al. 2012

View full text Add to dashboard Cite

BackgroundThe objective of this systematic review was to examine the benefits, harms and pharmacokinetic interactions arising from the co-administration of commonly used dietary supplements with cardiovascular drugs. Many patients on cardiovascular drugs take dietary supplements for presumed benefits and may be at risk for adverse supplement-drug interactions.MethodsThe Allied and Complementary Medicine Database, the Cochrane Library, EMBASE, International Bibliographic Information on Dietary Supplements and MEDLINE were searched from the inception of the review to October 2011. Grey literature was also reviewed.Two reviewers independently screened records to identify studies comparing a supplement plus cardiovascular drug(s) with the drug(s) alone. Reviewers extracted data using standardized forms, assessed the study risk of bias, graded the strength of evidence and reported applicability.ResultsEvidence was obtained from 65 randomized clinical trials, 2 controlled clinical trials and 1 observational study. With only a few small studies available per supplement, evidence was insufficient for all predefined gradable clinical efficacy and harms outcomes, such as mortality and serious adverse events. One long-term pragmatic trial showed no benefit from co-administering vitamin E with aspirin on a composite cardiovascular outcome. Evidence for most intermediate outcomes was insufficient or of low strength, suggesting no effect. Incremental benefits were noted for triglyceridemia with omega-3 fatty acid added to statins; and there was an improvement in levels of high-density lipoprotein cholesterol with garlic supplementation when people also consumed nitratesConclusionsEvidence of low-strength indicates benefits of omega-3 fatty acids (plus statin, or calcium channel blockers and antiplatelets) and garlic (plus nitrates or warfarin) on triglycerides and HDL-C, respectively. Safety concerns, however, persist.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Interactions of commonly used dietary supplements with cardiovascular drugs: a systematic review

et al. 2012

View full text Add to dashboard Cite

show abstract

“…62,86 Decreased platelet aggregation has been demonstrated with EPA supplementation in some 87,88 but not all studies. 89,90 EPA can also reduce the expression of vascular cell adhesion molecule-1 (VCAM-1), endothelial leukocyte adhesion molecule-1 (E-selectin or ELAM-1), and inter cellular adhesion molecule-1 (ICAM-1). 91 These adhesion molecules are elevated in CHF and plasma levels are related to the severity of the condition.…”

Section: Potential Effects Of ω-3 Pufas In Chronic Heart Failurementioning

confidence: 99%

Marine polyunsaturated fatty acids in heart failure Are the theoretical benefits matched by the clinical data?

Witte

Clark²

2009

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

“…Ingestion of n-3 fatty acids leads to suppression of TX A2 synthesis by platelets and by blood mononuclear cells [87,88]. Decreased platelet aggregation has been demonstrated with EPA supplementation in some [89][90][91] but not all studies [92][93][94].…”

Section: Haemostasismentioning

confidence: 99%

Fish oils – adjuvant therapy in chronic heart failure?

Witte

Clark

2004

European Journal of Cardiovascular Prevention & Rehabilitat

View full text Add to dashboard Cite

Despite advances in medical management and device therapy, chronic heart failure (CHF) remains a condition of high mortality and poor quality of life. Patients with CHF endure frequent admissions to hospital, with exacerbations of breathlessness or recurrent acute myocardial infarction and have a high incidence of sudden death. A high intake of marine polyunsaturated fatty acids (PUFAs) is associated with lower cardiovascular mortality in the general population, and diabetics, and can reduce cardiovascular deaths post-infarction. Many of the effects of PUFAs could be of benefit in CHF patients. They can improve endothelial function, reduce vascular tone, reduce platelet aggregability, improve myocardial relaxation, stabilize myocardial cells by prolonging the refractory period, and lead to increased appetite and weight gain. They also have potentially important immune-modulating effects, reducing cytokine production and release and altering prostaglandin metabolism. In this review article we discuss the potential benefits of PUFA supplementation in CHF patients using data from clinical trials and in vitro experiments.

show abstract

The acute and short-time effect of supplementation with the combination of n−3 fatty acids and acetylsalicylic acid on platelet function and plasma lipids

Cited by 28 publications

References 22 publications

Interactions of commonly used dietary supplements with cardiovascular drugs: a systematic review

Interactions of commonly used dietary supplements with cardiovascular drugs: a systematic review

Marine polyunsaturated fatty acids in heart failure Are the theoretical benefits matched by the clinical data?

Fish oils – adjuvant therapy in chronic heart failure?

Contact Info

Product

Resources

About